BACKGROUND: Sinusoidal obstruction syndrome (SOS) is a serious complication of hematopoietic stem cell transplantation (HSCT), with a mortality rate of up to 90%. We report our experience on the use of defibrotide for SOS prophylaxis in HSCT. MATERIAL AND METHODS: We retrospectively reviewed data of 49 patients who received defibrotide as SOS prophylaxis during the course of HSCT at the National Cancer Center, Goyang, Korea, between August 2005 and July 2008. RESULTS: Thirty-four patients (69.4%) were classified as a high-risk group for developing SOS. Defibrotide was well-tolerated, without any grade 3 or 4 toxicity. The median value of maximum total bilirubin within 100 days after HSCT was within the normal range. SOS was diagnosed in only 1 patient, who underwent autologous HSCT due to relapsed medulloblastoma. There was no day 100 treatment-related mortality in our study. CONCLUSIONS: Defibrotide appears to be a safe prophylaxis for SOS. This study suggests that it could be effective to use prophylactic defibrotide in advance to improve HSCT outcomes in patients at risk of SOS.
BACKGROUND:Sinusoidal obstruction syndrome (SOS) is a serious complication of hematopoietic stem cell transplantation (HSCT), with a mortality rate of up to 90%. We report our experience on the use of defibrotide for SOS prophylaxis in HSCT. MATERIAL AND METHODS: We retrospectively reviewed data of 49 patients who received defibrotide as SOS prophylaxis during the course of HSCT at the National Cancer Center, Goyang, Korea, between August 2005 and July 2008. RESULTS: Thirty-four patients (69.4%) were classified as a high-risk group for developing SOS. Defibrotide was well-tolerated, without any grade 3 or 4 toxicity. The median value of maximum total bilirubin within 100 days after HSCT was within the normal range. SOS was diagnosed in only 1 patient, who underwent autologous HSCT due to relapsed medulloblastoma. There was no day 100 treatment-related mortality in our study. CONCLUSIONS:Defibrotide appears to be a safe prophylaxis for SOS. This study suggests that it could be effective to use prophylactic defibrotide in advance to improve HSCT outcomes in patients at risk of SOS.
Authors: Christopher Strouse; Paul Richardson; Grant Prentice; Sandra Korman; Robin Hume; Bijan Nejadnik; Mary M Horowitz; Wael Saber Journal: Biol Blood Marrow Transplant Date: 2016-04-19 Impact factor: 5.742
Authors: Mohamad Mohty; Florent Malard; Manuel Abecasis; Erik Aerts; Ahmed S Alaskar; Mahmoud Aljurf; Mutlu Arat; Peter Bader; Frederic Baron; Grzegorz Basak; Ali Bazarbachi; Didier Blaise; Fabio Ciceri; Selim Corbacioglu; Jean-Hugues Dalle; Fiona Dignan; Takahiro Fukuda; Anne Huynh; Jurgen Kuball; Silvy Lachance; Hillard Lazarus; Tamas Masszi; Mauricette Michallet; Arnon Nagler; Mairead NiChonghaile; Shinichiro Okamoto; Antonio Pagliuca; Christina Peters; Finn B Petersen; Paul G Richardson; Tapani Ruutu; Wael Saber; Bipin N Savani; Robert Soiffer; Jan Styczynski; Elisabeth Wallhult; Ibrahim Yakoub-Agha; Rafael F Duarte; Enric Carreras Journal: Bone Marrow Transplant Date: 2019-10-01 Impact factor: 5.483
Authors: Seom Gim Kong; Je-Hwan Lee; Young Tak Lim; Ji Hyun Lee; Hyeon-Seok Eom; Hyewon Lee; Do Young Kim; Sung-Nam Lim; Sung-Soo Yoon; Sung-Yong Kim; Ho Sup Lee Journal: Korean J Intern Med Date: 2021-12-14 Impact factor: 2.884